Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs

Drugs of the Future

Volumn 29, Issue 8, 2004, Pages 807-819

  Papadopoulou, Maria V ^a   Bloomer, William D ^a  

^a Evanston Northwestern Healthcare ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALIPHATIC COMPOUND; ALIPHATIC N OXIDE DERIVATIVE; AROMATIC COMPOUND; AROMATIC NITRO COMPOUND; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; ETANIDAZOLE; HYPOXIA ACTIVATED BIOREDUCTIVE AGENT; MELPHALAN; MISONIDAZOLE; MITOMYCIN C; NITRACRINE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; NITROIMIDAZOLE LINKED ACRIDINE DERIVATIVE; NITROIMIDAZOLE LINKED PHENANTHRIDINE DERIVATIVE; NITROQUINOLINE DERIVATIVE; NLCQ 1; NSC 709257; PACLITAXEL; PORFIROMYCIN; QUINONE DERIVATIVE; RB 90740; RECOMBINANT DNA; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL TISSUE; BINDING AFFINITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DISSOCIATION; DNA ALKYLATION; DNA BINDING; DRUG DIFFUSION; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INTERCALATION COMPLEX; MALE; NONHUMAN; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; RAT; RETINA INJURY; REVIEW; SOLID TUMOR;

EID: 6344292451     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.08.819391     Document Type: Review

References (95)

1. Hockel, M., Schlenger, K., Mitze, M. et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996, 6: 3-9.
2. Siemann, D.W. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 1984, 10: 1585-94.
3. Grau, C., Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 1988, 13: 301-9.
4. Brown, J.M. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today 2000, 6(4): 157-62.
5. Cuvier, C., Jang, A., Hill, R.P. Exposure to hypoxia, glucose starvation and acidosis: Effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 1997, 15: 19-25.
6. Graham, C.H., Forsdike, J., Fitzgerald, C.J. et al. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999, 80: 617-23.
7. Hockel, M., Schlenger, K., Aral, B. et al. Association between tumor hypoxia and malignant progression in advanced cancer of uterine cervix. Cancer Res 1996, 56: 4509-15.
8. Stratford, I.J., Workman, P. Bioreductive drugs into the next millennium. Anticancer Drug Design 1998, 13: 519-28.
9. Denny, W.A. Prodrug strategies in cancer therapy. Eur J Med Chem 2001, 36: 577-95.
10. Brown, M.J., Lemmon, M.J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990, 50: 7745-9.
11. Langmuir, V.K., Rooker, J.A., Osen, M. et al. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 1994, 54: 2845-7.
12. Siemann, D.W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother Oncol 1995, 34: 47-53.
13. Papadopoulou, M.V., Ji, M., Bloomer, W.D. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 1996, 10: 49-58.
14. Papadopoulou, M.V., Ji, M., Rao, M.K. et al. 9-[3-(2-Nitro-1-imidazolyl) propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 1996, 8: 425-34.
15. Papadopoulou, M.V., Ji, M., Rao, M.K. et al. 9-[3-(2-Nitro-1-imidazolyl) propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol Res 1997, 9: 249-57.
16. Dorie, M.J., Brown, J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 1997, 39: 361-6.
17. Patterson, L.H., McKeown, S.R. AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000, 83(12): 1589-93.
18. Gallagher, R., Hughes, C.M., Murray, M.M. et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001, 85: 625-9.
19. Rockwell, S., Sartorelli, A.C., Tomasz, M. et al. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metast Rev 1993, 12: 165-76.
20. Belcourt M.F., Hodnick W.F., Rockwell, S. et al. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul 1998, 38: 111-33.
21. Pavlidis N., Hanauske, A.R., Gamucci, T. et al. A randomized phase II study with two schedules of the novel indoloquinone E09 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 1996, 7: 529-31.
22. Tomasz M., Palom Y. The mitomycin bioreductive antitumor agents: Cross-linking and alkylation of DNA as the molecular basis of their activity (review). Pharmacol Ther 1997, 76: 73-8.
23. Beall H.D., Winski, S.L. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development (review). Front Biosci 2000, 5: D632-48.
24. Craighead, P.S. Pearcey, R., Stuart, G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000, 48: 781-95.
25. von Pawel, J., von Roemeling, R., Gatzemeier, U. et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J Clin Oncol 2000, 18: 1351-9.
26. Del Rowe, J., Scott, C., Werner-Wasik, M. et al. Single-arm, open label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000, 18: 1254-9.
27. Rishin, D., Peters, L., Hicks, R. et al. Phase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19: 535-42.
28. Aquino, V.M., Weitman, S.D., Winick, N.J. et al. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 2004, 22: 1413-9.
29. Evans, J.W., Yudoh, K., Delahoussaye, Y.M. et al. Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res 1998, 58: 2098-101.
30. Delahoussaye, Y.M., Evans, J.W., Brown, J.M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 2001, 62: 1201-9.
31. Delahoussaye, Y.M., Hay, M.P., Pruijn, F.B. et al. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol 2003, 65: 1807-15.
32. Hay, M.P., Pruijn, F.B., Gamage, S.A. et al. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: Potent analogs of the hypoxia-selective cytotoxin tirapazamine. J Med Chem 2004, 47: 475-88.
33. Ortega, M.A., Morancho, M.J., Martinez-Crespo, F.J. et al. New quinoxaline-carbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. Eur J Med Chem 2000, 35: 21-30.
34. Naylor, M.A., Adams, G.E., Haigh, A. et al. Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo. Anti-Cancer Drugs 1995, 6: 259-69.
35. Benghiat A., Steward, W.P., Loadman, P.M. et al. Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report. Proc Am Soc Clin Oncol 2004, 23: 149.
36. Wilson, W.R., van Zijl, P., Denny, W.A. Bis-bioreductive agents as hypoxia-selective cytotoxins: Nitracrine N-oxide. Int J Radiat Oncol Biol Phys 1992, 22: 693-7.
37. Lee, H.H., Wilson, W.R., Ferry, D.M. et al. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J Med Chem 1996, 39: 2508-17.
38. Lee, H.H., Wilson, W.R., Denny, W.A. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity. Anti-Cancer Drug Design 1999, 14: 487-97.
39. Ware, D.C., Palmer, B.D., Wilson, W.R. et al. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt (III) complexes of bidentate mustards. J Med Chem 1993, 36: 1839-46.
40. Dearling, J.L., Lewis, J.S., Mullen, G.E. et al. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998, 25: 788-92.
41. 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000, 41: 169-76.
42. Denny, W.A., Wilson, W.R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells. J Med Chem 1986, 29: 879-87.
43. Jenkins, T.C., Naylor, M.A., O'Neill, P. et al. Synthesis and evaluation of a-[[(2-halo-ethyl)aminolmethyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of a-[(1-aziridinyl) methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively-activated cytotoxins. J Med Chem 1990, 33: 2603-10.
44. Cole, S., Stratford, I.J., Bowler, J. et al. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int J Radiat Oncol Biol Phys 1991, 21: 387-95.
45. Siemann, D.W. In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145. Int J Radiat Oncol Biol Phys 1994, 29: 301-6.
46. Cowan, D.S.M., Panicucci, R., McClelland, R.A. et al. Targeting radiosensitizers to DNA by attachment of an intercalating group: Nitroimidazole-linked phenanthridines. Radiat Res 1991, 127: 81-89.
47. Papadopoulou, M.V., Bloomer, W.D. Nitroheterocyclic-linked acridines as DNA-targeting bioreductive agents. Drugs Fut 1993, 18(3): 231-8.
48. Hay, M.P., Wilson, W.R., Moselen, J.W. et al. Hypoxia-selective antitumor agents. 8. Bis-(nitroimidazolyl)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J Med Chem 1994, 37: 381-91.
49. Hay, M.P., Lee, H.H., Wilson, W.R. et al. Hypoxia-selective antitumor agents. 10. Bis(nitroimidazoles) and related bis(nitro-heterocycles): Development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. J Med Chem 1995, 38: 1928-41.
50. Hay, M.P., Sykes, B.M., Denny, W.A. et al. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]1,2- dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett 1999, 15: 2237-42.
51. Wilson, W.R., Thompson, L.H., Anderson, R.F. et al. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine analogues. J Med Chem 1989, 32: 31-8.
52. Breider, M.A., Pilcher, G.D., Graziano, M.J. et al. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 1998, 26: 234-9.
53. Moselen, J.W., Hay, M.P., Denny, W.A. et al. N-(2-(2-Methyl-5- nitroimidazolyl)-ethyl)-4-(2-nitroimidazolyl)butanamide (NNB, NSC 639862), a bis-bioreductive agent with marked selective toxicity towards hypoxic cells. Cancer Res 1995, 55: 574-80.
54. Wilson, W.R., Denny, W.A., Stewart, G.M. et al. Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int J Radiat Oncol Biol Phys 1986, 12: 1235-8.
55. Wilson, W.R., Denny, W.A. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In: Radiation Research, a Twentieth-Century Perspective, Vol. 2. W.C. Dewey, M. Edington, R.J.M. Fry, E.J. Hall, G.F. Whitmore (Eds.). Academic Press: San Diego, 1992, 796-801.
56. Rosenzweig, H.S., Papadopoulou, M.V., Bloomer, W.D. A study of the interaction of NLA-compounds with topoisomerases I and II. Proc-Am Assoc Cancer Res 1994, 35: 362.
57. Wilson, W.R., Anderson, R.F., Denny, W.A. Hypoxia-selective agents. 1. Relationship between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitroacrines. J Med Chem 1989, 32: 23-30.
58. Wilson, W.R., Siim, B.G., Denny, W.A. et al. 5-Nitraquine, a new DNA-affinic hypoxic cell radiosensitizer: Comparison with nitracrine. Radiat Res 1992, 131: 257-65.
59. Palmer, B.D., Wilson, W.R., Cliffe, S. et al. Hypoxia-selective antitumor agents. 5. Synthesis of water soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem 1992, 35: 3214-22.
60. Lewis, D.F.V. Molecular orbital calculations on tumor-inhibitory phenyl aziridines: QSARs. Xenobiotica 1989, 19: 243-51.
61. Palmer, B.D., Wilson, W.R., Pullen, S.M. et al. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl) anilines. J Med Chem 1990, 33: 112-21.
62. Lee, H.H., Palmer, B.D., Wilson, W.R. et al. Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard. Bioorg Med Chem Lett 1998, 8: 1741-4.
63. Carl, P.L., Charkravarty, P.K., Katzenellenbogen, J.A. A novel connector linkage applicable in prodrug design. J Med Chem 1981, 24: 479-80.
64. Denny, W.A., Wilson, W.R., Hay, M.P. Recent developments in the design of bioreductive drugs. Br J Cancer 1996, 74(Suppl. 27): S32-8.
65. Hay, M.P., Wilson, W.R., Denny, W.A. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett 1999, 9: 3417-2.
66. Papadopoulou, M.V., Rosenzweig, H.S., Doddi, M. et al. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res 1994, 6: 439-48.
67. Papadopoulou, M.V., Ji, M., Rao, M.K. et al. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 2000, 12: 185-92.
68. Papadopoulou, M.V., Rosenzweig, H.S., Bloomer, W.D. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers. Bioorg Med Chem Lett 2004, 14: 1519-22.
69. 19F- Magnetic Resonance Spectroscopy (MRS). In vivo 2001, 15: 365-72.
70. Papadopoulou, M.V., Wang, R., Bloomer, W.D. Nitroimidazole-based bioreductive compound bearing a pyridopyridine chromophore. 47th Ann Meet Radiat Res Soc/18th Ann Meet North Am Hyperthermia Soc (April 29-May 3, Albuquerque) 2000, Abst P269.
71. Papadopoulou, M.V., Wang, R., Bloomer, W.D. Nitroimidazole-based bioreductive compound bearing a quinazoline chromophore. 47th Ann Meet Radiat Res Soc/18th Ann Meet North Am Hyperthermia Soc (April 29-May 3, Albuquerque) 2000, Abst P270.
72. Papadopoulou, M.V., Ji, M., Rao, M.K. et al. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 2000, 12: 325-33.
73. Papadopoulou, M.V., Ji, X., Xue, C. et al. In vitro schedule-dependent potentiation of taxol, 5FU and cisDDP by the hypoxic cytotoxin NLCQ-1. Comparison with tirapazamine. 11th Int Conf Chem Modifiers Cancer Treat. Tumor Physiol Cancer Treat (Oct 5-7, Banff) 2000, Abst 58.
74. Papadopoulou, M.V., Rosenzweig, H.S., Ji, M. et al. 9-[3-(2-Nitro-1- imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: Mechanistic studies. II. Oncol Res 1998, 10: 163-73.
75. Papadopoulou, M.V., Ji, M., Khan, S.H. et al. Mechanistic studies regarding the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Oncol Res 1999, 11: 345-57.
76. Papadopoulou, M.V., Xue, C., Bloomer, W.D. The involvement of DNA repair genes in the hypoxia-dependent NLCQ-1 (NSC 709257) toxicity and its synergistic interaction with cisplatin or melphalan. 12th Int Cong Radiat Res (Aug 17-22, Brisbane) 2003, Abst P05/1185.
77. Papadopoulou, M.V., Ji, X., Bloomer, W.D. Mechanisms involved in the potentiation of paclitaxel or 5-FU by the hypoxic cytotoxin NLCQ-1. Clin Cancer Res 2001, 7(11, Suppl.): 3679.
78. Papadopoulou, M.V., Ji, M., Bloomer, W.D. THNLA-1 as radio/ chemosensitizer of EMT-6 tumors in mice. Br J Cancer 1996, 74(Suppl. 27): S267-70.
79. Papadopoulou, M.V., Bloomer, W.D., Hollingshead, M.G. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Proc Am Assoc Cancer Res 2004, 45: 954.
80. Papadopoulou, M.V., Ji, M., Bloomer, W.D. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo. Oncol Res 2003, 13: 561-6.
81. Papadopoulou, M.V., Ji, M., Bloomer, W.D. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 1998, 42: 775-9.
82. Papadopoulou, M.V., Ji, M., Ji, X. et al. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chemother Pharmacol 2002, 50: 501-8.
83. Papadopoulou, M.V., Ji, M., Bloomer, W.D. et al. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol 2002, 2(5): 298-305.
84. Papadopoulou, M.V., Ji, M., Ji, X. et al. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chemother Pharmacol 2002, 50: 291-8.
85. Papadopoulou, M.V., Ji, M., Ji, X. et al. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo. Comparison with tirapazamine. Oncol Res 2002, 13: 47-54.
86. Papadopoulou, M.V., Ji, M., Bloomer, W.D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 2001, 48(2): 160-8.
87. Blumenthal, R.D., Taylor, A., Osorio, L. et al. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 2001, 94: 564-71.
88. Papadopoulou, M.V., Bloomer, W.D., Torti, V.R. et al. Pilot, five-day repeat dose toxicity study of NLCQ-1 (NSC 709257) in Sprague Dawley rats. Clin Cancer Res 2003, 9(16, Suppl., Pt. 2): 6084S.
89. Papadopoulou, M.V., Bloomer, W.D., Torti, V.R. et al. IND-directed, five-day repeat dose toxicity study of NLCQ-1 (NSC 709257) administered with or without Taxol® in Sprague Dawley rats. Proc Am Assoc Cancer Res 2004, 45: 485.
90. Papadopoulou, M.V., Ji, X., Bloomer, W.D. Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice. Proc Am Assoc Cancer Res 2002, 43: 1092.
91. Reid, J.M., Squillace, D.P., Ames, M.M. Single dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 Mice. Cancer Chemother Pharmacol 2003, 51: 483-7.
92. O'Brien, R.L., Hahn, F.E. Chloroquine structural requirements for binding to deoxyribonucleic acid and antimalarial activity. Antimicrob Agents Chemother 1965, 315-20.
93. Wilson, W.R. Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand (unpublished results, personal communication).
94. Papadopoulou, M.V., Ji, M., Rao, M.K. et al. Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 2003, 14: 21-9.
95. Lee, A.E., Wilson, W.R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000, 163: 50-9.